Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

Clinical trial NCT04675710 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04675710
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Thyroid Gland Anaplastic Carcinoma Thyroid Gland Squamous Cell Carcinoma

Start date: 2021-06-24
Primary completion: 2026-10-30
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.